FIGURE 1
Non-metastatic groups |
||||
Characteristics |
Patients < 40 years (N=8) |
Patients 40 yean (N=16) |
Total (N=24) |
P |
Average age |
34.75 (SD= 3.12) |
63.86($D=7.56) |
<0.001 |
|
Male |
3(37.5%) |
8(50%) |
11(43.75%) |
|
Female |
5(62.5%) |
8(50%) |
13(56.25%) |
|
Primary tumour location |
1 |
|||
Colon |
3(37.5%) |
6(37.5%) |
9(37.5%) |
|
Rectum |
5(62.5%) |
10 (62.5%) |
15(62.5%) |
|
T of TNM |
0.5754 |
|||
T1 |
1(12.5%) |
2(12.5%) |
3(12.5%) |
|
T2 |
0 |
2(12.5%) |
2(6.25%) |
|
T3 |
7(87.5%) |
12 (75%) |
19 (81.25%) |
|
T4 |
0 |
0 |
0 |
|
N of TNM |
0.0627 |
|||
NO |
4(50%) |
9(56.25%) |
13(53.125%) |
|
N1 |
0 |
5(31.25%) |
5(15.625%) |
|
N2 |
4(50%) |
2(12.5%) |
6(31.25%) |
|
TNM stage |
1 |
|||
0-II |
4(50%) |
9(56.25%) |
13 (43.75%) |
|
III |
4(50%) |
7 (43.75 %) |
11(56.25%) |
|
Tumour differentian |
0.8485 |
|||
Well |
2(25%) |
5(33.33%) |
7 (29.165 %) |
|
Moderate |
5(62.5%) |
9(60%) |
14(61.25%) |
|
Poorly |
1(12.5%) |
1(6.67%) |
2(9.585%) |
|
Histological type |
1 |
|||
Adenocarcinoma |
7(87.5%) |
15(93.75%) |
22(90.625%) |
|
Mucinous adenocarcinoma |
1(12.5%) |
1(6.25%) |
2(9.375%) |
|
Lymphatic invasion |
1 |
|||
Yes |
2(25%) |
4(25%) |
6(25%) |
|
No |
6(75%) |
12 (75%) |
18(75%) |
|
Vascular invasion |
1 |
|||
Yes |
1(12.5%) |
3(18.75%) |
5(15.625%) |
|
No |
7(87.5%) |
13(81.25%) |
19 (84.375 %) |
|
Perineural invasion |
0.6311 |
|||
Yes |
1(12.5%) |
4(25%) |
5(18.75%) |
|
No |
7(87.5%) |
12(75%) |
19 (81.75 %) |
|
CEA before surgery |
1 |
|||
55 ng/ml |
7(87.5%) |
14(87.5%) |
21(87.5%) |
|
> 5 ng/ml |
1(12.5%) |
2(12.5%) |
3(12.5%) |
|
CA19.9 before surgery |
0.3333 |
|||
S UI/ml |
7(87.5%) |
16(100%) |
23(93.75%) |
|
> 37 UI/ml |
1(12.5%) |
0 |
1(6.25%) |
|
Neoadjuvant treatment |
0.3521 |
|||
Yes |
7(87.5%) |
10 (62.5%) |
17(75%) |
|
No |
1(12.5%) |
6(37.5%) |
7(25%) |
|
Number of chemotherapy lines |
0.5808 |
|||
0-1 |
4(50%) |
11(68.75%) |
15(59.375%) |
|
Table 1: Patients Characteristics for non-metastatic patients
Metastatic Group |
||||
Characteristics |
Patients < 40 years (N=23) |
Patients > 40 years (N=46) |
Total (N=69) |
P |
Average age |
34.69 (SD= 4.74) |
59.74 (SD=9.8) |
<0.001 |
|
Male |
12 (52.17 %) |
18 (39.13%) |
30 (45.65% |
|
Female |
11 (47.83 %) |
28 (60.87 € %) |
39 (54.35%) |
|
Neoadjuvant treatment |
0.3 |
|||
Yes |
12 (52.17 %) |
18 (39.13 € %) |
30 (45.65%) |
|
No |
11 (47.83 %) |
28 (60.87° |
39 (54.35%) |
|
Number of chemotherapy |
0.873 |
|||
0-1 |
4 (17.39 %) |
7 (15.22% |
11 (16.305%) |
|
2 |
4 (17.39 %) |
11 (23.91%) |
15 (20.65%) |
|
> 2 |
15 (65.22 %) |
28 (60.87%) |
43 (63.045 ° |
|
Targeted therapy |
0.71 |
|||
Yes |
17 (73.91 %) |
32 (69.57%) |
49 (71.74%) |
|
No |
6 (26.09 %) |
14 (30.43%) |
20 (28.26 %) |
|
Family history |
0.1078 |
|||
Yes |
2 (8.7 %) |
0 |
2 (4.35 %) |
|
No |
21 (91.3 %) |
46 (100 %) |
66 (95.65 %) |
|
KRAS mutation |
1 |
|||
Yes |
6 (26.09 %) |
12 (26.67 %) |
18 (26.38 %) |
|
No |
17 (73.91 %) |
33 (73.33 %) |
50 (72.62 %) |
|
NRAS mutation |
1 |
|||
Yes |
0 |
0 |
0 |
|
No |
22 (100 %) |
45 (100 %) |
67 (100%) |
|
BRAF mutation |
0.3212 |
|||
Yes |
3 (9.52 %) |
2 (4.44 %) |
5 (6.98%) |
|
No |
19 (90.48 %) |
43 (95.56 %) |
62 (93.02% |
|
Microsatellite instability |
0.2157 |
|||
MSS |
19 (82.61 %) |
42 (93.33 %) |
61 (87.97 %) |
|
MSI |
4 (17.39 %) |
3 (6.67 %) |
7 (12.03 %) |
|
Duration of symptoms |
0.3457 |
|||
1< month |
7 (38.89 %) |
18 (45%) |
25 (41.945%) |
|
1-3 month |
5 (27.78 %) |
9 (22.5%) |
14 (25.14%) |
|
> 3 months |
6 (33.33%) |
8 (20%) |
14 (26.665%) |
|
Table 2: Patients Characteristics for metastatic patients
Metastatic patients |
Non-metastatic patients |
Primary tumour location (colon or rectum) |
Primary tumour location (colon or rectum) |
CEA before surgery (or >5) |
TNM |
CA19.9 before surgery (37 or> 37) |
T (0-4) |
Metastatic site |
N (0-2) |
Liver |
TNM stage (I-III) |
Peritoneum |
Tumour differentiation (well, moderate, poorly) |
Liver & peritoneum |
Histological type (adenocarcinoma, mucinous) |
Synchronous metastasis |
Lymphatic invasion |
Metachronous metastasis |
Vascular invasion |
If PM |
Perineural invasion |
PCI score (≤7 or > 7) |
CEA before surgery (≤5 or >5) |
If LM |
CA19.9 before surgery (≤37 or >37) |
Table 1s: Matching factors for metastatic and non-metastatic patients For primary tumour location, we consider the following as “right colon”: caecum and right colon”: transverse colon, left colon and sigmoid and “rectum”: recto-sigmoid junction, rectum.
Non-metastatic groups |
||||
Symptoms |
Patients s 40 years (N=8) |
Patients > 40 years (N=16) |
Total |
P |
Abdominal pain |
1 |
|||
Yes |
3 (37.5 %) |
5 (31.25 %) |
8 (34.375%) |
|
No |
5 (62.5 %) |
11 (68.75 %) |
16 (65.625%) |
|
Rectal bleeding |
0.1893 |
|||
Yes |
7 (87.5 %) |
9 (56.25 %) |
16 (71.875%) |
|
No |
1 (12.5 %) |
7 (43.75 %) |
8 (28.125%) |
|
Weight loss |
1 |
|||
Yes |
1 (12.5 %) |
1 (6.25 %) |
2 (9.375 %) |
|
No |
7 (87. %) |
15 (93.75 %) |
22 (90.625 %) |
|
Occlusion |
1 |
|||
Yes |
0 |
1 (6.25 %) |
1 (3.125%) |
|
No |
8 (100 %) |
15 (93.75 %) |
13(96.875%) |
|
Constipation |
0.3625 |
|||
Yes |
4 (50 %) |
4 (25 %) |
8 (37.5 %) |
|
No |
4 (50 %) |
12 (75 %) |
16 (62.5%) |
|
Diarrhoea |
0.5362 |
|||
Yes |
0 |
2 (12.5 %) |
2 (6.25%) |
|
No |
8 (100 %) |
14 (87.5 %) |
22 (93.75 %) |
|
Peritonitis or bowel perforation |
1 |
|||
Yes |
0 |
0 |
0 |
|
No |
8 (100 %) |
16 (100 %) |
24 (100 %) |
|
Melena |
0.6311 |
|||
Yes |
1 (12.5 %) |
4 (25 %) |
5 (18.75 %) |
|
No |
7 (87.5 %) |
12 (75 %) |
19 (81.25 %) |
|
Change in bowel habits |
1 |
|||
Yes |
2 (25 %) |
4 (25 %) |
6 (25%) |
|
No |
6 (75%) |
12 (75 %) |
18 (75%) |
|
Iron deficiency anaemia |
0.6311 |
|||
Yes |
1 (12.5 %) |
4 (25 %) |
5 (18.75%) |
|
No |
7 (87.5 %) |
12 (75 %) |
19 (81.25 %) |
|
Weakness, fatigue |
1 |
|||
Yes |
1 (12.5 %) |
1 (6.25 %) |
2 (9.375%) |
|
No |
7 (87.5 %) |
15 (93.75 %) |
22(90.625% |
|
Rectal pain |
1 |
|||
Table 2s: Symptoms in non-metastatic patients
Metastatic groups |
||||
Symptoms |
Patients s 40 years (N= 23) |
Patients > 40 years (N=46) |
Total |
P |
Abdominal pain |
0.07 |
|||
Yes |
17 (80.95 %) |
25 (58.14%) |
42 (69.545%) |
|
No |
4 (19.05 %) |
18 (41.86 %) |
22 (30.455%) |
|
Rectal bleeding |
0.41 |
|||
Yes |
8 (38.1 %) |
12 (27.91 %) |
20 (31.25%) |
|
No |
13 (61.9 %) |
31 (72.09 %) |
49 (68.25%) |
|
Weight loss |
0.0013 |
|||
Yes |
8 (38.1 %) |
2 (4.65 %) |
10 (15.63%) |
|
No |
13 (61.9 %) |
41 (95.35 %) |
54 (84.38%) |
|
Occlusion |
0.39 |
|||
Yes |
7 (33.33 %) |
10 (23.26 %) |
17 (26.56%) |
|
No |
14 (66.67 %) |
33 (76.74 %) |
47 (73.44%) |
|
Constipation |
0.04 |
|||
Yes |
9 (42.86 %) |
8 (18.6 |
17 (26.56 %) |
|
No |
12 (57.1 14 %) |
35 (81.4%) |
(73.44%) |
|
Diarrhoea |
0.4215 |
|||
Yes |
4 (19.05 %) |
4 (9.3%) |
8 (12.5%) |
|
No |
17 (80.95 %) |
39 (90.7%) |
56 (87.5%) |
|
Peritonitis or bowel |
0.4762 |
|||
Yes |
2 (9.52 %) |
8 (18.6) %) |
10 (15.63%) |
|
No |
19 (90.48 %) |
35 (81.4 %) |
54 (84.38 %) |
|
Melena |
0.1042 |
|||
Yes |
2 (9.52 %) |
0 |
2 (3.13%) |
|
No |
19 (90.48 %) |
43 (100 %) |
62 (96.88 %) |
|
Change in bowel habits |
0.54 |
|||
Yes |
11 (52.38 %) |
19 (44.19% |
(46.88% |
|
No |
10 (47.62 %) |
24 (55.81%) |
(53.13%) |
|
Iron deficiency anaemia |
0.4215 |
|||
Yes |
4 (19.05 %) |
4 (9.3 ° %) |
8 (12.5%) |
|
No |
17 (80.95 %) |
39 (90.7 %) |
56 (87.5%) |
|
Weakness, fatigue |
1 |
|||
Yes |
2 (9.52 %) |
5 (11.63 %) |
7 (10.94%) |
|
No |
19 (90.48 %) |
38 (88.37%) |
57 (89.06%) |
|
Rectal pain |
0.3202 |
|||
Table 3s: Symptoms in metastatic patients
.JPG)
.JPG)
.JPG)
.JPG)
Tables at a glance
Figures at a glance